Structure-based discovery of small molecules improving stability of human broadly-neutralizing anti-HIV antibody 2F5 in plant suspension cells

Biotechnol J. 2022 Apr;17(4):e2100266. doi: 10.1002/biot.202100266. Epub 2022 Feb 3.

Abstract

The production of biopharmaceuticals in engineered plant-based systems is a promising technology that has proven its suitability for the production of various recombinant glyco-proteins that are currently undergoing clinical trials. However, compared to mammalian cell lines, the productivity of plant-based systems still requires further improvement. A major obstacle is the proteolytic degradation of recombinant target proteins by endogenous plant proteases mainly from the subtilisin family of serine proteases. In the present study, the authors screened for putative small molecule inhibitors for subtilases that are secreted from tobacco BY-2 suspension cells using an in silico approach. The effectiveness of the substances identified in this screen was subsequently tested in degradation assays using the human broadly-neutralizing anti-HIV monoclonal antibody 2F5 (mAb2F5) and spent BY-2 culture medium as a model system. Among 16 putative inhibitors identified by in silico studies, three naphthalene sulfonic acid derivatives showed inhibitory activity in in vitro degradation assays and are similar to or even more effective than phenylmethylsulfonyl fluoride (PMSF), a classical inhibitor of serine proteases, which served as positive control.

Keywords: biopharmaceuticals; molecular farming; protease inhibitor; protein modeling; virtual screening.

MeSH terms

  • Animals
  • HIV Antibodies* / metabolism
  • HIV Envelope Protein gp41 / metabolism
  • HIV-1*
  • Humans
  • Mammals
  • Nicotiana / genetics
  • Nicotiana / metabolism
  • Recombinant Proteins / metabolism
  • Serine Proteases / metabolism

Substances

  • HIV Antibodies
  • HIV Envelope Protein gp41
  • Recombinant Proteins
  • Serine Proteases